As a result of the new customer implementation and other positive business developments, CorMedix (CRMD) is increasing its second quarter net sales guidance from the previously communicated $31M to a range of $35M to $40M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter